Novo Nordisk shares technical analysis: Resistance test at $49.91 in focus

Traders Union
All News
Stocks
Novo Nordisk jumps 3.68% after Q2 beat

Highlights

Novo Nordisk upgraded its full-year outlook after second-quarter 2026 profit and margin expansion exceeded expectations.
Quarterly revenue reached $12 billion, with annual revenue at $46.70 billion and net profit at $15.48 billion, showing strong earnings power.
Shares of Novo Nordisk gained 3.68% to $48.65, with technical signals showing continued bullish momentum and a projected range of $47.39 to $49.91.

Profit beat and outlook upgrade fuel investor demand

Novo Nordisk delivered a strong second-quarter 2026 profit beat, highlighting realized margin expansion and better-than-expected operating performance according to Gurufocus. The company upgraded its full-year outlook, which reflects confidence in ongoing business momentum and directly improves investor sentiment. Robust quarterly revenue of $12 billion, driven by strong uptake of oral Wegovy, confirms underlying top-line growth, while the latest annual figures of $46.70 billion in revenue and $15.48 billion in net profit further anchor the company's earnings power. Together, these developments have reinforced demand for NVO stock and explain the positive move on the day.

Strong momentum reinforces bullish structure above technical support

NVO remains above primary support levels, with the MA-20 at $47.36, MA-50 at $46.51 on the H1 chart, and the MA-200 at $46.41 on the daily chart. The Ichimoku Kijun at $47.39 is acting as immediate support. Momentum indicators reinforce the bullish structure: MACD and ADX both confirm sustained buying pressure, while RSI is elevated at 72.96, and Stochastic RSI, CCI, and Bull/Bear Power all show overbought conditions consistent with dominant buyer activity. The Awesome Oscillator supports the ongoing positive trend, and across all intraday technicals, there is no sign of negative divergence.

Upside bias dominates as tight price range contains risks

In the near term, NVO is expected to remain within a price range of $47.39 to $49.91, a volatility band relative to current levels. There is a 79% probability scenario targeting further upside within this corridor, while the risk of a downside move is limited to a 21% probability. A break above $49.91 would open the way for further gains, while a loss of support at $47.39 could drive a corrective move lower.

Viktoras Karapetjanc, analyst at Traders Union, sees Novo Nordisk’s strong Q2 profit beat and upgraded outlook as clear signals of realized business strength and growing investor confidence. He believes recent price action is fundamentally supported by rising revenues and sustained momentum in core products. Current technicals and sentiment indicators reinforce a constructive view. "With robust results in place and momentum favoring buyers, the setup points to further gains so long as support at $47.39 is preserved."

Earlier, analysts noted that Novo Nordisk's technical strength and expanding clinical pipeline were supporting a bullish outlook for the stock. The current market action and improving financial results reinforce this view, with the immediate range between $47.39 and $49.91 serving as the key zone for potential breakout or corrective movement ahead.

Source of Data: NVO Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.